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Summary:
In order to improve prediction of hematopoietic recov-
ery, we conducted a pilot study, analyzing the signifi-
cance of growth factor receptor expression in autografts
as well as endogenous growth factor levels in blood
before, during and after stem cell transplantation.
Three early acting (stem cell factor (SCF), Flt3 ligand
(Flt3) and fetal antigen 1 (FA1)) and three lineage-
specific growth factors (EPO, G-CSF and thrombopoie-
tin (Tpo)) were analyzed by ELISA in 16 patients with
multiple myeloma (MM) and 16 patients with non-
Hodgkin’s lymphoma (NHL). The relative number of
SCF, Flt3, Tpo and G-CSF receptor positive, CD34+
progenitor cells were measured by flow cytometry in the
leukapheresis product used for transplantation in a
subgroup of 15 patients (NHL, n = 8, MM, n = 7). Three
factors were identified as having a significant impact on
platelet recovery. First, the level of Tpo in blood at the
time of the nadir (day +7). Second, the percentage of
re-infused thrombopoietin receptor positive progenitors
and finally, the percentage of Flt3 receptor positive
progenitors. On the other hand, none of the analyzed
factors significantly predicted myeloid or erythroid
recovery. These findings need to be confirmed in pro-
spectively designed studies. Bone Marrow Transplan-
tation (2000) 26, 525–531.
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Hematopoietic reconstitution after myeloablative chemo-
therapy and stem cell transplantation depends upon the
quality and quantity of the re-infused stem cells, the
microenvironment in the bone marrow, and the different
growth factors affecting homing, proliferation and differen-
tiation of the ‘new’ stem cells in a sequential manner.1 Stem
cell factor (SCF) and Flt3 ligand (Flt3) have been shown
to be of major importance for the proliferation and differen-
tiation of early stem cells, and for the expansion of the
progenitor cell compartment, acting in synergy with later
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acting growth factors. The early acting growth factors are
intimately related to the stromal microenvironment. SCF
exerts its action in small niches of proliferating, self-
renewing stem cells between stromal fibroblasts and endo-
thelial cells, excreting growth factors.2 Like SCF, Flt3
stimulates proliferation and differentiation of stem and pro-
genitor cells in synergy with other growth factors.3 FA1 is
the soluble product of delta-like (dlk) – a mRNA encoding
a transmembrane protein that contains six epidermal growth
factor (EGF)-like domains. FA1 includes all six EGF
domains but lacks the juxtamembrane, transmembrane and
cytoplasmic regions of dlk.4 Recently, in vitro experiments
have demonstrated that FA1 can act as a hematopoietic
regulator by promoting cobblestone area colony formation
in stromal monolayers. The resulting stem cells are trans-
plantable and repopulate in animal models.5 Erythropoietin
(EPO), granulocyte colony-stimulating factor (G-CSF) and
thrombopoietin (Tpo) as well as the corresponding receptor
positive progenitors are considered essential for develop-
ment of the lineage-specific progenitors.6–9 Recently, Tpo
has been demonstrated to be of importance in the early
development of the stem cell.10
The successful outcome of high-dose therapy depends
upon early engraftment and blood cell recovery, since mor-
bidity and mortality are closely related to the duration of
neutropenia and thrombocytopenia.11 Prediction of patients
at risk of late hematopoietic recovery would make it pos-
sible to target growth factor treatment in a more rational
manner.
Concentrations of growth factors in the blood are influ-
enced by the interaction between the growth factors and
their target cells via the specific receptor binding.1 Pro-
duction, distribution and elimination of the growth factor
and proliferation, maturation and apoptosis of the target
cells affect the blood concentration in different ways.12–14
In this context, information about concentrations of growth
factors in peripheral blood alone might be more confusing
than informative. Consequently, we have analyzed growth
factor concentrations during the course of autologous stem
cell transplantation as well as the autograft content of
growth factor receptor positive CD34+ progenitor cells,
aiming to identify new important factors for early blood
cell recovery. The results obtained from this pilot study are
meant to provide a basis for larger, prospective studies.
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Materials and methods
Patients and treatment
Thirty-two patients were included in the study, 16 with
intermediate/high-grade non-Hodgkin’s lymphoma and 16
with multiple myeloma. The patients were selected on the
basis of diagnosis and a full set of available blood samples
before and during high-dose chemotherapy followed by
autologous transplantation at the Department of Hemato-
logy, Herlev Hospital during the years 1993–1998. The two
disease groups were comparable with respect to age, gender
and courses of prior chemotherapy and/or radiation therapy
(Table 1). All patients exhibited normal kidney and liver
function at the time of transplantation.
The conditioning regimen before transplantation was
BEAM for the NHL patients (BCNU 300 mg/m2 day - 7,
etoposide 200 mg/m2 and ara-C 100 mg/m2 twice daily for
4 days (day - 6 to day - 3) melphalan 140 mg/m2 once on
day - 2). Patients with multiple myeloma were treated with
high-dose melphalan (200 mg/m2) on day - 3. Stem cells
were collected earlier by leukapheresis after priming with
high-dose cyclophosphamide (4 g/m2) and G-CSF
(filgrastim, 5 mg/kg bodyweight) from day 8 after cyclo-
phosphamide and until leukapheresis had been completed.
Leukapheresis was carried out using a CS 3000 Plus cell
separator (Baxter, Deerfield, IL, USA) as previously
described.15 The product was evaluated by enumeration of
CD34+ cells according to the Nordic Protocol.16 The stem
cells were re-infused on day 0. Four patients with NHL and
eight patients with MM received exogenous, recombinant
human G-CSF at some time during the course of trans-
Table 1 Patient characteristics
Characteristic NHL MM P
Number of patients 16 16
Age, years 46 (19–65) 55 (37–61) NS
CR at PBSCT
1st or 2nd CR 5 7 NS
Prior chemotherapy
induction 8 7 NS
induction + radiation 2 4 NS
more than above 6 5 NS
Previously oral therapy
(chlorambucil/melphalan) 4 4 NS
CD34+ cells · 106/kg in 5.6 (1.5– 7.9 (2.0– NS
leukapheresis product 21.9) 51.6)
Reticulocyte recovery
(days until retics .0.2%) 10 (7–15) 11 (7–37+) NS
Hb <10.5 g/dl (days) 9 (3–32) 9.5 (2–37) NS
Neutrophil recovery
(days until ANC .0.5 · 109/l) 12 (9–28) 14 (10–40) NS
ANC <0.5 · 109/l (days) 11 (7–18) 10.5 (5–38) NS
Platelet recovery
(days until platelets .20 · 109/l) 14.5 (8–60) 13.5 (0– NS
37+)
Platelets <20 · 109/l (days) 10.5 (3–38) 6.5 (1–27+) NS
Characteristics in a total of 32 patients undergoing autologous stem cell
transplantation. Values are median (range). P values calculated by Fisher’s
exact test or Mann–Whitney U test.
NHL = non-Hodgkin’s lymphoma; MM = multiple myeloma; NS = not
significant; CR = complete remission; PBSCT = peripheral blood stem
cell transplantation; ANC = absolute neutrophil count.
plantation after clinical judgment or according to an ongo-
ing Nordic Myeloma Protocol. These patients were ana-
lyzed separately for endogenous G-CSF and neutrophil
behavior.
All patient-related data, including the peripheral blood
cell counts, were retrospectively obtained from the patient
records. In the case of reticulocyte counts, the relative
rather than absolute number of reticulocytes was used
because red cell numbers were unavailable.
Sample preparations and analyses
Blood samples were obtained at least once a week for all
patients from 1 to 2 weeks before and up until 4 weeks
after transplantation (day 0). The samples were immedi-
ately centrifuged for 10 min at 3000 g. Plasma and/or
serum was separated and stored at - 20° C. Plasma from
eight healthy donors, treated the same way, served as a
control. In the case of FA1, the reference range had pre-
viously been established from the sera of 75 healthy
adults.17 After thawing, plasma or serum (or both) were
analyzed for growth factor content by the ELISA technique,
using sensitive and specific, commercially available kits
(R&D Systems, Minneapolis, MN, USA). In the case of
FA1, the concentrations were analyzed by a newly
developed ELISA technique as described.17 The sensitivity
of this assay is ,0.4 ng/ml. According to the manufac-
turer’s information, the sensitivity of the commercial kits
is for EPO ,0.6 mIU/ml, for G-CSF 7 pg/ml, for Tpo
,15 pg/ml, for SCF ,4 pg/ml and for Flt3 ,7 pg/ml. Ser-
ial dilutions were used if concentrations were higher than
the maximum detection level. All measurements were per-
formed in duplicate and the mean used for comparisons.
Samples of mononuclear cells, separated by density cen-
trifugation from the leukaphereses, were re-suspended in a
medium containing 95% fetal calf serum and 5% DMSO
under sterile conditions, frozen and kept at - 80° C. After
thawing, the samples were separately analyzed for receptor
concentrations in eight NHL patients and seven MM
patients (eight MM patients were analyzed for SCF and G-
CSF receptors) by using fluorescence-marked growth fac-
tors and monoclonal anti-CD34 antibodies, and subsequent
detection by flow cytometry.
Flow cytometry for progenitor subsets
The growth factor receptor positivity for Tpo, SCF and Flt3
receptors was detected in the leukapheresis product by
double-staining the cells with a phycoerythrin (PE)-conju-
gated monoclonal antibody against CD34 (Anti-HPCA-2
PE, Becton Dickinson, San Jose, CA, USA, 10 mg/ml in
50 ml) and biotinylated growth factors and fluorescein
isothiocyanate (FITC)-conjugated avidin. In the case of the
G-CSF receptor, FITC-conjugated anti-CD34 was used
(anti-HPCA-2 FITC, Becton Dickinson, 10 mg/ml in 50 ml)
together with directly PE-conjugated G-CSF. All the
growth factor receptor concentrations were analyzed using
modified flow cytometry kits (Fluorokine from R&D
Systems). Approximately 1 · 106 cells in 50 ml were incu-
bated with the biotinylated or PE-conjugated growth factor
for 60 min at 4 ° C. The second step, with no prior wash,
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was incubation with avidin-FITC (10 mg/ml in 50 ml) and
the CD34 antibody for 30 min at 4° C in the dark. Since we
analyzed receptor positivity on a minor fraction of frozen
mononuclear cells, we used more cells and more conjugated
growth factor than recommended by the manufacturer
(50 ml of each: SCF 1 mg/ml, Flt3 and Tpo 5 mg/ml and
G-CSF 7.5 mg/ml). Accordingly, this was one of the
reasons for choosing the biotin–avidin system. Another rea-
son was that Tpo was unavailable in a conjugated form for
flow cytometry. As a negative staining control for the
biotin-conjugated growth factors, it was important to use
an irrelevant molecule, biotinylated like the growth factors.
A soybean trypsin inhibitor that was biotinylated to the
same degree as the growth factors (5 mg/ml in 50 ml) was
included as suggested by the manufacturer. For the G-CSF
receptor, we used IgG1 PE (Becton Dickinson), CD34 FITC
as a negative control. In all cases, the fractions of marked
cells were subsequently analyzed in a CD34+ acquisition
gate, using a FACScan Flow Cytometer equipped with an
argon laser (Becton Dickinson). First, a wide, rectangular
live gate was set on the isotype control (IgG1 FITC, IgG1
PE from Becton Dickinson, each 5 mg/ml in 50 ml) in a
forward (FSC) - side light scatter (SSC) plot, to exclude
cellular debris. After acquisition of 50 000 events from an
IgG1/CD34 sample, a rectangular CD34-positive acqui-
sition gate was set in a fluorescence against SSC plot. Most
samples were also run without acquisition gate to enable
establishment of the best negative control afterwards. Most
of the leukapheresis products were analyzed with propid-
ium iodide (PI; Sigma, St Louis, MO, USA) also, in order
to estimate the number of viable cells (PI in PBS was used
at a concentration of 0.5 mg/ml).
The leukapheresis products were pre-treated in the fol-
lowing manner: after careful thawing, the product was sus-
pended in cold PBS and remaining erythrocytes were lysed
in Ortho-mune Lysing Reagent (Ortho Diagnostic Systems,
Raritan, NJ, USA). The samples were washed twice
(centrifugation by 1500 r.p.m. at 4° C for 5 min) and re-
suspended in a phosphate-buffered saline solution contain-
ing natriumazide 0.5 g/l (FACS-PBS). Finally, the samples
were filtered, and the cells counted on a Coulter MDII
(Coulter, Miami, FL, USA), centrifuged again and incu-
bated with growth factors and/or antibodies after re-suspen-
sion in 0.25–0.5 ml FACS-PBS.
Hematopoietic recovery, definitions
The endpoints we used for analyses of erythropoiesis were:
the number of days before the relative reticulocyte count
exceeded 0.2%, the exact number of days with reticulocyte
counts below or equal to 0.2%, and the number of days
with a hemoglobin concentration less than or equal to
10.5 g/dl. The number of red blood cell transfusions was
also recorded.
Analyses of neutropenia were made with the following
endpoints: the number of days before the absolute neutro-
phil count (ANC) exceeded 0.5 · 109/l, the absolute num-
ber of days with ANC below or equal to this figure, and
the absolute number of days with ANC less than or equal
to 0.2 · 109/l. Thrombocytopenia was analyzed with the
following endpoints: the number of days before the platelet
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count exceeded 20 · 109/l, the absolute number of days
below or equal to this figure, and the number of days with
platelet counts less than or equal to 10 · 109/l.
Statistics
Patient characteristics were analyzed by Fisher’s exact test
and groups compared by non-parametric methods (Mann–
Whitney U test) with median values as the best represen-
tation. All relationships between engraftment and growth
factor/growth factor receptor concentrations were analyzed
by survival statistics with comparison of Kaplan–Meier
curves for different groups by the logrank test. Data from
two patients who died before engraftment were censored.
In all tests a P value ,0.05 was considered significant. All
statistical analyses were carried out using the software Stat-
View 4.0 (Abacus Concepts, Berkeley, CA, USA).
Results
Growth factor fluctuations and hematopoietic recovery
All patients reached a nadir of peripheral blood values at
day +7 with reticulocyte counts close to 0%, absolute neu-
trophil counts of 0.0 to 0.1 · 109/l and platelets below
20 · 109/l. Two patients died in the nadir period; one
patient with a highly malignant, anaplastic NHL in second
PR on day 15, and one patient with progressive MM on
day 37.
No significant differences were found between growth
factor concentrations in the two disease groups during or
after transplantation, except on day 0. This difference was
most likely caused by a difference in peripheral blood cell
decline due to different conditioning. For the early acting
growth factors SCF, FA1 and Flt3, the pre-transplantation
level was also higher in the patients with MM. No differ-
ences were found between the disease groups in the recep-
tor analyses. In the following post-transplant analyses, data
from all patients are pooled.
An inverse relation was observed between the peripheral
blood cell counts and the concentrations of progenitor-spe-
cific growth factors (Figure 1). The median growth factor
concentrations for patients and controls are shown in Table
2. The duration of nadir was analyzed by the method of
Kaplan and Meier. The patients were divided in two
groups: those with peak growth factor concentrations (day
+7) above the median value and those with concentrations
below or equal to the median value.
Regarding erythroid engraftment, we found no differ-
ences in duration of erythroid nadir between patients with
high or low median peak values of erythropoietin, no matter
how the endpoint was defined. For neutrophil engraftment,
we compared those who had absolute neutrophil counts of
<0.5 · 109/l with patients who had achieved neutrophil
counts above this value on day +14. G-CSF was significantly
different in these two groups, with median concentrations day
+7 at 885 and 3680 pg/ml (P = 0.025), respectively, the group
with high G-CSF concentrations being more likely to
experience fast engraftment. The survival analyses were,
however, unable to demonstrate significant differences in
neutropenia for G-CSF high/low level patients.
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Figure 1 Relationship between progenitor-specific growth factors and
peripheral blood cells after autologous stem cell transplantation.
Fluctuations in (a) reticulocyte counts (%) and erythropoietin
concentrations; (b) absolute neutrophil counts (· 109/l) and G-CSF
concentrations; and (c) thrombocyte counts (· 109/l) and thrombopoietin
concentrations in peripheral blood before and after transplantation (day
- 7 until day +14). Stem cells were reinfused day 0. Points represent means
and bars represent 95% confidence intervals.
As regards the recovery of thrombopoiesis, patients with
platelet counts <20 · 109/l were compared to patients who
had achieved platelets above this level on day +14. Median
Tpo concentrations day +7 were highest in the group with
late engraftment (platelets <20 · 109/l), but the difference
was not significant (median 2000 vs 1587, P = 0.17). This
relationship was evident and significant in the survival
analysis as well, no matter how the period of nadir was
defined (Figure 2).
Table 2 Fluctuations in growth factor concentrations
Growth factor Day - 7 Day +7 Day +14 Donors
median
(range)
EPO 17 99 18 1.5
(mIU/ml) (2–195) (22–304) (0–.600) (0–11)
G-CSF 0 1610 63 0.0
(pg/ml) (0–101) (289–.25 000) (0–.2500) (0–0)
Tpo (pg/ml) 233 1757 1744 66
(36–.2000) (946–.6000) (418–.6000) (18–260)
SCF (pg/ml) 1359 1623 1673 1584
(694–2075) (1202–.2000) (1086–1932) (701–1979)
FA1 (ng/ml) 19.2 21.4 23.5 25.8a
(10–43.6) (8.7–53.9) (11.7–56.2) (7.6–64.2)
Flt3 (pg/ml) 171 3144 1412 94
(63–359) (406–4712) (161–4846) (49–211)
Variations in growth factor concentrations, median and (range) in blood
from 32 patients before (day - 7) and after (day +7 and day +14)
autologous stem cell transplantation and in eight healthy subjects. Stem
cells were reinfused day 0.
aPre-established normal range and median from 75 healthy donors.
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Figure 2 Relationship between thrombocytopenia and thrombopoietin
levels after autologous stem cell transplantation. Kaplan–Meier survival
plot of (a) the number of days with platelet counts <20 · 109/l or (b)
<10 · 109/l and Tpo concentration high (. median, O) or low (< median,
i) in the blood day +7 after reinfusion of autologous stem cells in 32
patients with NHL or MM.
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emerged as significantly important factors for erythroid,
neutrophil or platelet recovery in the survival analyses.
Receptor positive CD34+ subsets and hematopoietic
recovery
After subtraction of background staining, SCF receptors
were determined on 0 to 28%, Flt3 receptors on 0 to 22%,
Tpo receptors (c-mpl) on 0 to 18% and G-CSF receptors
on 3 to 44% of the CD34+ cells (Figure 3).
Survival statistics on receptor positivity and engraftment
identified Tpo and Flt3 receptor positivity as having a sig-
nificant impact on the duration of thrombocytopenia, for
any chosen endpoint of platelet nadir (Figure 4). The Tpo
receptor positivity was high in all patients with fast recov-
ery and low in those with slow recovery, regardless of the
reinfused number of CD34+ cells (Table 3).
In six patients treated with recombinant human G-CSF,
G-CSF receptor positivity correlated by simple regression
analysis to the number of days with deep neutropenia
(r = 0.90, P = 0.02 for days with ANC <0.2 · 109/l), i.e.
patients with many receptor positive CD34+ progenitors had
a less profound neutropenia than patients with a low G-CSF
receptor positivity when treated with rhG-CSF. No other
receptor analysis correlated with hematopoietic recovery
following transplantation.
Discussion
Autologous stem cell transplantation preceded by high-dose
chemotherapy exerts the maximal stimulus for hemato-
poietic recovery. We know that the reconstitution of hema-
topoiesis requires a precise and complex coordination of
growth factors. When this process takes place after stem
cell transplantation, recovery may correlate with the growth
factor and growth factor receptor status in the patient. The
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Figure 3 Flow cytometric detection of growth factor receptors in a leukapheresis product. Flow cytometric analysis of SCF receptor, Flt3 receptor, G-
CSF receptor and Tpo receptor (c-mpl) positive subsets of CD34+ progenitors from a representative leukapheresis product. The cells were co-stained
with labeled ligands (biotin-conjugated SCF, Flt3 or Tpo, or PE-conjugated G-CSF) and anti-CD34 (PE- or FITC-conjugated). Fluorescence profiles of
growth factor receptor expression are indicated by solid lines. Dotted lines indicate negative controls. The CD34+ acquisition gate (R1) and the CD34+
analysis gate (R2) is shown in a CD34-SSC dot plot along with the IgG control.
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Figure 4 Relationship between thrombocytopenia and growth factor
receptor positivity in the autograft. Kaplan–Meier survival plot of days
with platelet counts <20 · 109/l after autologous stem cell transplantation
in 15 patients with NHL or MM. The patients are divided by high (. median,
O) or low (< median, i) percentage of (a) Tpo receptor positive, CD34+
reinfused stem cells or (b) Flt3 receptor positive, CD34+ reinfused stem cells.
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Table 3 Characteristics of 15 patients and their autografts
Patient No. Diagnosis rhG-CSF Reinfused CD34+ CD34+ c-mpl+ CD34+ Flt3+ Trc <20 · 109/l Trc <10 · 109/l Tpo in blood
– (day) cells ( · 106/kg) cells (%) cells (%) (days) (days) day +7 (pg/ml)
1 NHL + (1–14) 5.0 0 1 12 2 1379
2 NHL + (4–20) 2.8 0 2 21 10 .6000
3 NHL – 4.0 1 6 11 2 2010
4 NHL – 2.4 2 10 6 1 946
5 NHL – 1.5 1 1 23 6 2404
6 NHL – 4.6 7 3 7 1 1583
7 NHL – 21.9 1 1 6 2 2368
8 NHL – 5.6 8 3 3 1 1590
9 MM + (6–12) 4.8 1 8 3 1 1757
10 MM + (1–14) 3.8 3 20 7 1 1901
11 MM + (2–37) 12.9 0 2 27 11 2000
12 MM + (3–13) 3.4 0 0 6 1 1660
13 MM – 51.6 10 22 1 0 1852
14 MM – 4.6 0 4 6 2 1248
15 MM – 13.5 18 18 2 2384
Individual data on exogenous G-CSF treatment, platelet recovery and flow cytometric characteristics of the autografts in 15 patients after autologous
stem cell transplantation. Day 0 is the day the autografts are re-infused.
NHL = non-Hodgkin’s lymphoma; MM = multiple myeloma; c-mpl = receptor for Tpo; Flt3 = receptor for Flt3 ligand; Trc = platelet counts in peripheral
blood; Tpo = thrombopoietin concentration.
problem is that the interactive nature of this process makes
it difficult to determine the relevant parameters to analyze.
It would, however, be of obvious benefit to know the
patients at risk of late engraftment at an early stage and
perhaps stratify the administration of recombinant growth
factors to these patients.
In the present pilot study, we have examined growth factor
concentrations and receptor positivity in the re-infused stem
cells and related these concentrations to the depth and duration
of hematological nadir, aiming to improve prediction of the
risk of late recovery. It seems possible to define a group of
patients at risk of prolonged thrombocytopenia before the
transplantation by flow cytometric detection of growth factor
receptor representation in the stem cell product, analyzing the
megakaryocytic CD34+/c-mpl+ and/or CD34+/Flt3+ progeni-
tors, corresponding to what has been demonstrated for
CD34+/CD61+ progenitors.18,19 The prediction may be con-
firmed by analyzing the concentration of thrombopoietin in
blood day +7 after re-infusion of the stem cells. A high Tpo
concentration and a low relative number of Tpo receptors and
Flt3 receptors in the autograft correlated in our study with a
slow recovery of platelets. The inverse relation between Tpo
concentration and Tpo receptor positive, CD34+ progenitor
cells is probably caused by elimination of Tpo from the blood
by binding to the target cells.20
The present study is not large enough to determine
whether receptor analysis provides a more precise predic-
tion than traditional CD34+ enumeration, but it does pro-
vide a basis for evaluation of new parameters in quality
assessment of autografts in a larger context.
We did not find any convincing predictive parameters
for recovery of erythropoiesis, being restricted by the retro-
spective and sometimes insufficient nature of our data.
Obviously, red blood cell transfusions might disturb the
picture as well. It is possible that a well-designed prospec-
tive study with flow cytometric quantification of median
reticulocyte reticulation will be more successful in answer-
ing this question.21
Our results suggest a relationship between a high G-CSF
concentration and fast recovery of neutrophils. Several
studies have been performed concerning this matter and
most studies find some relationship of G-CSF concen-
trations with engraftment.6,12 Only a few studies have been
unable to demonstrate this relationship, and they included
patients with predominantly myeloid diseases, mostly
CML, undergoing allogeneic transplantation.22,23 Apart
from different study set-ups, including different statistical
methods, it could very well be that the endogenous G-CSF
response is dependent on more variables, like for example
severe infections, than is Tpo. An interesting finding was
that the number of G-CSF receptor positive CD34+ cells in
the autograft seemed to be important for the outcome of
recombinant human G-CSF treatment.
If these observations are confirmed they will provide pre-
dictive information on the outcome of treatment with
recombinant growth factors in the peripheral blood stem
cell transplantation setting.
There are several parameters that we have not been able
to take into consideration. Among them are the density of
the growth factor receptors on the stem cell and the affinity
of the ligand binding to the receptor. These factors are not
very well described and might be of equal importance.
Technical problems related to the method of flow cyto-
metric quantification of growth factor receptors are far from
solved. First, analyses on frozen material are difficult, since
the behavior of the cells is clearly different from that of
‘fresh’ cells. Defining relevant negative controls is also a
matter of great importance and controversy. In our study,
we used the biotin–avidin system and with the amount of
unspecific staining in this system, we chose to use an irrel-
evant protein marked the same way rather than ‘cold’
growth factor. Which procedure is more correct is difficult
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to determine and may, to a large extent, depend on the
nature of the study material.
The present study adds to the accumulating evidence
supporting the theory that measurements of endogenous
growth factor and growth factor receptor profiles in the
course of autologous transplantation in hematological
patients may provide significant information on
engraftment in the individual patient.
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